Search

Your search keyword '"Stilgenbauer, Stephan"' showing total 39 results

Search Constraints

Start Over You searched for: Author "Stilgenbauer, Stephan" Remove constraint Author: "Stilgenbauer, Stephan" Journal leukemia Remove constraint Journal: leukemia
39 results on '"Stilgenbauer, Stephan"'

Search Results

2. The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma—a randomized, open-label phase III trial of the European mantle cell lymphoma network

3. The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab

4. Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial

5. Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial

6. The scaffold protein NEDD9 is necessary for leukemia-cell migration and disease progression in a mouse model of chronic lymphocytic leukemia

9. Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations

10. EOMES and IL-10 regulate antitumor activity of T regulatory type 1 CD4+ T cells in chronic lymphocytic leukemia

11. Mutational mechanisms shaping the coding and noncoding genome of germinal center derived B-cell lymphomas

12. Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial

13. COVID-19 among fit patients with CLL treated with venetoclax-based combinations

14. Prognostic model for newly diagnosed CLL patients in Binet stage A: results of the multicenter, prospective CLL1 trial of the German CLL study group

15. Influence of obesity and gender on treatment outcomes in patients with chronic lymphocytic leukemia (CLL) undergoing rituximab-based chemoimmunotherapy

17. Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study

18. Oxidative stress as candidate therapeutic target to overcome microenvironmental protection of CLL

20. Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemia

22. CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia

24. ERIC recommendations for TP53mutation analysis in chronic lymphocytic leukemia—2024 update

26. Longitudinal analyses of CLL in mice identify leukemia-related clonal changes including a Myc gain predicting poor outcome in patients

27. Influence of obesity and gender on treatment outcomes in patients with chronic lymphocytic leukemia (CLL) undergoing rituximab-based chemoimmunotherapy

28. Elevated Hedgehog activity contributes to attenuated DNA damage responses in aged hematopoietic cells

29. Longitudinal analyses of CLL in mice identify leukemia-related clonal changes including a Mycgain predicting poor outcome in patients

30. Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study

31. The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab

32. Oxidative stress as candidate therapeutic target to overcome microenvironmental protection of CLL

34. CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia

35. EOMES and IL-10 regulate antitumor activity of T regulatory type 1 CD4+T cells in chronic lymphocytic leukemia

36. Control of chronic lymphocytic leukemia development by clonally-expanded CD8+ T-cells that undergo functional exhaustion in secondary lymphoid tissues

37. EOMES is essential for antitumor activity of CD8+T cells in chronic lymphocytic leukemia

38. Control of chronic lymphocytic leukemia development by clonally-expanded CD8+T-cells that undergo functional exhaustion in secondary lymphoid tissues

39. Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia

Catalog

Books, media, physical & digital resources